2.07
+2.48%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cerus
From its filings with the US Securities and Exchange Commission
Cerus is based in Concord, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CERS. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $233.8m and a net loss of $15.6m. At that date it held total assets of $221.9m and shareholders' equity of $64.2m. By business, Product [Member] brought in 88.2% of revenue, followed by Government Contract [Member] at 11.8%.
We are a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on our proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Our INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex, or IFC, and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received a broad range of regulatory approvals and certification, including but not limited to FDA approval in the U.S., CE Certificates of Conformity delivered in accordance with the Medical Devices Regulation 2017/745, or MDR, permitting us to affix the CE Mark to our products and place them on the market in the European Union and other jurisdictions that recognize the CE Mark, and are being marketed and sold in a number of countries around the world, including the U.S., certain countries in Europe, the Commonwealth of Independent States, or CIS, the Middle East, and Latin America and selected countries in other regions of the world. Additionally, we have received FDA approval for the INTERCEPT Blood System for Cryoprecipitation.
Quoted from its 10-K, filed 2 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 31 Jan 1997
- Employees
- 275
- Website
- cerus.com ↗
- Head office
- 1220 CONCORD AVENUE, CONCORD, CA, 94520
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Mr. William GreenmanChairman of the Board, President, Chief Executive Officer, since 2006$3.0m
- Mr. Kevin GreenChief Financial Officer, Vice President - Finance$1.3m
- Mr. Vivek JayaramanChief Operating Officer$1.5m
- Ms. Chrystal JensenChief Legal Office, General Counsel and Secretary$1.1m
- Dr. Richard BenjaminChief Medical Officer$1.1m
- Dr. Frank WitneyLead Independent Director$141,600
- Mr. Dean GregoryDirector$132,000
- Mr. Eric BjerkholtIndependent Director$130,350
- Ms. Ann LucenaIndependent Director$146,600
- Mr. Timothy MooreIndependent Director$133,600
- Ms. Jami NachtsheimIndependent Director$130,600
- Dr. Hua ShanIndependent Director$126,038
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 35
- Environment
- 4
- Social
- 39
- Governance
- 63
- Women in the workforce
- 62%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cerus Corp has innovative technology that allows for safer blood transfusions, reducing the risk of transfusion-transmitted infections.
- The company has established partnerships with major blood centers and hospitals, providing a strong distribution network.
- Cerus Corp's products have gained regulatory approvals in multiple countries, indicating their adherence to global quality standards.
Weaknesses
- Cerus Corp is heavily dependent on its flagship product, the INTERCEPT Blood System, which generates a significant portion of its revenue. Any disruption in production or supply chain issues could have a detrimental impact on the company.
- The company faces intense competition from other blood safety technology providers, which could potentially limit market share and profitability.
Opportunities
- With an increasing focus on patient safety and infection prevention, there is a growing demand for blood safety solutions, providing Cerus Corp with opportunities for market expansion.
- The company can explore strategic partnerships or acquisitions to enhance its product portfolio and diversify its revenue streams.
Threats
- Changes in regulations or standards related to blood safety could pose challenges for Cerus Corp and require significant modifications to its products and processes.
- Economic downturns or changes in healthcare spending patterns may impact the affordability and demand for Cerus Corp's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.